China Medical System Holdings Limited プレスリリース一覧

CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China Mar 13, 2026 22:00 JST More info..

CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China Dec 15, 2025 21:00 JST More info..

CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China Dec 11, 2025 21:00 JST More info..

CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
Oct 30, 2025 21:00 JST

China Medical System Holdings Limited ("CMS") is pleased to announce that its subsidiary, Dermavon Holdings Limited ("Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection ("MG-K10" or the "Product").
More info..

CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis(R) and Beovu(R) Oct 27, 2025 23:00 JST More info..

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
Sep 28, 2025 16:00 JST

China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by CMS on 22 April 2025 for details) together with its subsidiaries, obtained positive results from the phase 3 clinical trial (the “Trial”) of ruxolitinib cream (the “Product”) in patients with mild to moderate atopic dermatitis (AD) in China.
More info..

China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies
Sep 23, 2025 13:15 JST

China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the "Agreements") with Chongqing Genrix Biopharmaceutical Co., Ltd. ("Genrix Bio") for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, "Vecantoxatug") indicated for passive immunization against tetanus and Silevimig Injection (GR1801, "Silevimig") indicated for passive immunization following suspected rabies virus exposure, respectively.
More info..

CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers Aug 19, 2025 16:00 JST More info..

China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China
Jul 29, 2025 05:00 JST

China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) ("ZUNVEYL" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA).
More info..